Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?

Bibliography

• PRUSINER SB: Biology and genetics of prion diseases. Annu. Rev. Microbiol. (1994) 48:655-686.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB: Prions. Proc. Natl. Acad. Sci. USA (1998) 95:13363-13383.
   PubMed Web of Science ®Google Scholar
• BRANDNER S, ISENMANN S, RAEBER A et al.: Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature (1996) 379:339-343.
   PubMed Web of Science ®Google Scholar
• CLARKE AR, JACKSON GS, COLLINGE J: The molecular biology of prion propagation. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2001) 356:185-195.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B: Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. Br. Med. Bull. (2003) 66:109-120.
   PubMed Web of Science ®Google Scholar
• HUANG Z, PRUSINER SB, COHEN FE: Scrapie prions: a three-dimensional model of an infectious fragment. Fold. Dis. (1996) 1:13-19.
   PubMedGoogle Scholar
• DELEAULT NR, LUCASSEN RW, SUPATTAPONE S: RNA molecules stimulate prion protein conversion. Nature (2003) 425:717-720.
   PubMed Web of Science ®Google Scholar
• BROWN DR, SCHMIDT B, KRETZSCHMAR HA: Role of microglia and host protein in neurotoxicity of a prion protein fragment. Nature (1996) 380:345-347.
   PubMed Web of Science ®Google Scholar
• BROWN DR, KRETZSCHMAR HA: Microglia and prion disease: a review. Histol. Histopathol. (1997) 12:883-992.
   PubMed Web of Science ®Google Scholar
• REZAIE P, LANTOS PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Brain Res. Rev. (2001) 35:55-72.
   PubMed Web of Science ®Google Scholar
• BROWN DR: Prion protein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem. (1999) 73:1105-1113.
   PubMed Web of Science ®Google Scholar
• RAEBER AJ, RACE RE, BRANDNER S et al.: Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J. (1997) 16:6057-6065.
   PubMed Web of Science ®Google Scholar
• GIESE A, BROWN DR, GROSCHUP MH, FELDMANN C, HAIST I, KRETZSCHMAR HA: Role of microglia in neuronal cell death in prion disease. Brain Pathol. (1998) 8:449-457.
   PubMed Web of Science ®Google Scholar
• HEPPNER FL, AGUZZI A: Prion diseases. In: Nature Encyclopedia of Life Sciences. Nature Publishing Group, London, UK (2007) http://www.els.net/[doi:10.1038/ npg.els.0000428.
   Google Scholar
• KUBLER E, OESCH B, RAEBER AJ: Diagnosis of prion diseases. Br. Med. Bull. (2003) 66:267-279.
   PubMed Web of Science ®Google Scholar
• KNIGHT R: Creutzfeldt–Jakob disease: clinical features, epidemiology and tests. Electrophoresis (1998) 19:1306-13010.
   PubMed Web of Science ®Google Scholar
• GAMBETTI P, PARCHI P, PETERSEN RB, CHEN SG, LUGARESI E: Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol. (1995) 5:43-51.
   PubMed Web of Science ®Google Scholar
• BROWN P, PREECE M, BRANDEL JP et al.: Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 55:1075-1081.
   PubMed Web of Science ®Google Scholar
• SMITH PG: The epidemics of bovine spongiform encephalopathy and variant CJD; current status and future prospects. Bull. World Health Organ. (2003) 81:123-130.
   PubMed Web of Science ®Google Scholar
• BROWN P, BRANDEL JP, PREECE M, SATO T: Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology (2006) 67:389-393.
   PubMed Web of Science ®Google Scholar
• MEDORI R, TRITSCHLER HJ, LEBLANC A et al.: Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N. Engl. J. Med. (1992) 326:444-449.
   PubMed Web of Science ®Google Scholar
• FIORINO AS: Sleep, genes and death: fatal familial insomnia. Brain Res. Brain Res. Rev. (1996) 22:258-264.
   PubMed Web of Science ®Google Scholar
• LIBERSKI PP, BUDKA H: Gerstmann-Straussler-Scheinker disease. I. Human diseases. Folia Neuropathol. (2004) 42(Suppl. B):120-140.
   PubMedGoogle Scholar
• WILL RG, IRONSIDE JW, ZEIDLER M et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921-925.
   PubMed Web of Science ®Google Scholar
• BRUCE ME, WILL RG, IRONSIDE JW et al.: Transmission to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature (1997) 389:498-501.
   PubMed Web of Science ®Google Scholar
• IRONSIDE JW: Pathology of variant Creutzfeldt-Jakob disease. Arch. Virol. Suppl. (2000) 16:143-151.
   PubMedGoogle Scholar
• IRONSIDE JW, HEAD MW: Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. Curr. Top. Microbiol. Immunol. (2004) 284:133-159.
   PubMed Web of Science ®Google Scholar
• SPENCER MD, KNIGHT RSG, WILL RG: First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. Br. Med. J. (2002) 324:1479-1482.
   PubMed Web of Science ®Google Scholar
• WADSWORTH JD, HILL AF, BECK JA, COLLINGE J: Molecular and clinical classification of human prion disease. Br. Med. Bull. (2003) 66:241-254.
   PubMed Web of Science ®Google Scholar
• MÜLLER WE, LAPLANCHE JL, USHIJIMA H, SCHRODER HC: Novel approaches in diagnosis and therapy of Creutzfeldt Jakob disease. Mech. Ageing Dev. (2000) 16:193-218.
   Google Scholar
• HEAD MW, IRONSIDE JW: Inhibition of prion-protein conversion: a therapeutic tool? Trends Microbiol. (2000) 8:6-8.
   PubMed Web of Science ®Google Scholar
• LOVE R: Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet (2001) 358:563.
   PubMed Web of Science ®Google Scholar
• GILCH S, SCHATZL HM: Promising developments bringing prion diseases closer to therapy and prophylaxis. Trends Mol. Med. (2003) 9:367-369.
   PubMed Web of Science ®Google Scholar
• TREVITT CR, COLLINGE J: A systematic review of prion therapeutics in experimental models. Brain (2006) 129:2241-2265.
   PubMed Web of Science ®Google Scholar
• KOCISKO DA, CAUGHEY B, MORREY JD, RACE RE: Enhanced antiscrapie effect using combination drug treatment. Antimicrob. Agents Chemother. (2006) 50:3447-3449.
   PubMed Web of Science ®Google Scholar
• MCKENZIE D, KACZKOWSKI J, MARSH R, AIKEN J: Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J. Virol. (1994) 68:7534-7536.
   PubMed Web of Science ®Google Scholar
• DEMAIMAY R, RACE R, CHESEBRO B: Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J. Virol. (1999) 73:3511-3513.
   PubMed Web of Science ®Google Scholar
• ADJOU KT, DEMAIMAY R, DESLYS JP et al.: MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J. Gen. Virol. (1999) 80:1079-1085.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, RACE RE: Potent inhibition of scrapie associated PrP accumulation by Congo Red. J. Neurochem. (1992) 59:768-771.
   PubMed Web of Science ®Google Scholar
• CASPI S, HALIMI M, YANAI A, SASSON SB, TARABOULOS A, GABIZON R: The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. (1998) 273:3484-3489.
   PubMed Web of Science ®Google Scholar
• TAGLIAVINI F, MCARTHUR RA, CANCIANI B et al.: Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science (1997) 276:1119-1122.
   PubMed Web of Science ®Google Scholar
• MANUELIDIS L, FRITCH W, ZAITSEV I: Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet (1998) 352:456.
   PubMed Web of Science ®Google Scholar
• GILCH S, WINKLHOFER KF, GROSCHUP MH et al.: Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. (2001) 20:3957-3966.
   PubMed Web of Science ®Google Scholar
• SHYNG SL, LEHMANN S, MOULDER K, HARRIS D: Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein PrPc in cultured cells. J. Biol. Chem. (1995) 270:30221-30229.
   PubMed Web of Science ®Google Scholar
• PRIOLA SA, RAINES A, CAUGHEY WS: Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 287:1503-1506.
   PubMed Web of Science ®Google Scholar
• PEROVIC S, PERGANDE G, USHIJIMA H, KELVE M, FORREST J, MULLER WE: Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration (1995) 4:369-374.
   PubMedGoogle Scholar
• PEROVIC S, SCHLEGER C, PERGANDE G et al.: The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur. J. Pharmacol. (1994) 288:27-33.
   PubMed Web of Science ®Google Scholar
• OTTO M, CEPEK L, RATZKA P et al.: Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology (2004) 62:714-718.
   PubMed Web of Science ®Google Scholar
• DOH-URA K, IWAKI T, CAUGHEY B: Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. (2000) 74:4894-4897.
   PubMed Web of Science ®Google Scholar
• KORTH C, MAY BC, COHEN FE, PRUSINER SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA (2001) 98:9836-9841.
   PubMed Web of Science ®Google Scholar
• TURNBULL S, TABNER BJ, BROWN DR, ALLSOP D: Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. Neuroreport (2003) 14:1743-1745.
   PubMed Web of Science ®Google Scholar
• COLLINS SJ, LEWIS V, BRAZIER M, HILL AF, FLETCHER A, MASTERS CL: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. (2002) 52:503-506.
   PubMed Web of Science ®Google Scholar
• BARRET A, TAGLIAVINI F, FORLONI G et al.: Evaluation of quinacrine treatment for prion diseases. J. Virol. (2003) 77:8462-8469.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-LAGE JF, RABANO A, BERMEJO J et al.: Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg. Neurol. (2005) 64:542-545.
   PubMed Web of Science ®Google Scholar
• HAIK S, BRANDEL JP, SALOMON D et al.: Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology (2004) 63:2413-2415.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA M, YAMADA T, KUSUHARA T et al.: Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. (2004) 17:158-163.
   PubMed Web of Science ®Google Scholar
• DIRINGER H, EHLERS B: Chemoprophylaxis of scrapie in mice. J. Gen. Virol. (1991) 782:457-460.
   Google Scholar
• CAUGHEY B: Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosoaminoglycans? Biochem. Neurodegen. Disord. (1994) 22:163-167.
   Google Scholar
• CAUGHEY B, BROWN K, RAYMOND GJ, KATZENSTEIN GE, THRESHER W: Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red. J. Virol. (1994) 68:2135-2141.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, RAYMOND G: Sulfated polyanion inhibition of scrapie associated PrP accumulation in cultured cells. J. Virol. (1993) 67:643-650.
   PubMed Web of Science ®Google Scholar
• PEREZ M, WANDOSELL F, COLACO C, AVILA J: Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem. J. (1998) 335:369-374.
   PubMed Web of Science ®Google Scholar
• FARQUHAR C, DICKINSON A: Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before of after infection. J. Gen. Virol. (1986) 67:463-473.
   PubMed Web of Science ®Google Scholar
• EHLERS B, DIRINGER H: Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. (1984) 65:1325-1330.
   PubMed Web of Science ®Google Scholar
• KIMBERLIN RH, WALKER CA: Pathogenesis of experimental scrapie. Ciba Found. Symp. (1988) 135:37-62.
   PubMedGoogle Scholar
• LADOGANA A, CASACCIA P, INGROSSO L et al.: Sulphate polyanions prolong the incubation period of scrapie infected hamsters. J. Gen. Virol. (1992) 73:661-665.
   PubMed Web of Science ®Google Scholar
• FARQUHAR C, DICKINSON A, BRUCE M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
   PubMed Web of Science ®Google Scholar
• DOH-URA K, ISHIKAWA K, MURAKAMI-KUBO I et al.: Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. (2004) 78:4999-5006.
   Google Scholar
• DAWES J, PROWSE CV, PEPPER DS: Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb. Res. (1986) 44:683-693.
   PubMed Web of Science ®Google Scholar
• DAWES J, PEPPER DS: Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb. Haemost. (1992) 67:468-472.
   PubMed Web of Science ®Google Scholar
• MCGREGOR IR, DAWES J, PEPPER DS: Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides – comparison with effects upon anticoagulant activity, lipolysis and platelet A-granule proteins. Thromb. Haemost. (1985) 53:411-414.
   PubMed Web of Science ®Google Scholar
• SIE P, ALBAREDE JL, ROBERT M et al.: Tolerance and biological activity of pentosan polysulphate after intramuscular or subcutaneous administration for ten days in human volunteers. Thromb. Haemost. (1986) 55:86-89.
   PubMed Web of Science ®Google Scholar
• MULHOLLAND SG, HANNO P, PARSONS CL, SANT GR, STASKIN DR: Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology (1990) 35:552-558.
   PubMed Web of Science ®Google Scholar
• TARDY-PONCET B, TARDY B, GRELAC F et al.: Pentosan polysulfate induced thrombocytopaenia and thrombosis. Am. J. Haematol. (1994) 45:252-257.
   PubMed Web of Science ®Google Scholar
• EMMETT CJ, STEWART GR, JOHNSON RM, ASWANI SP, CHAN RL, JAKEMAN LB: Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp. Neurol. (1996) 140:151-160.
   PubMed Web of Science ®Google Scholar
• GILL SS, PATEL NK, HOTTON GR et al.: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson’s disease. Nat. Med. (2003) 9:589-595.
   PubMed Web of Science ®Google Scholar
• CORNFORD EM: The blood-brain barrier, a dynamic regulatory interface. Mol. Physiol. (1985) 7:219-260.
   Google Scholar
• NEUWELT EA: Mechanisms of disease: the blood-brain barrier. Neurosurgery (2004) 54:131-142.
   PubMed Web of Science ®Google Scholar
• KROLL RA, NEUWELT EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 42:1083-1100.
   PubMed Web of Science ®Google Scholar
• KEMPER EM, BOOGERD W, THUIS I, BEIJNEN JH, VAN TELLINGEN O: Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. (2004) 30:415-423.
   PubMed Web of Science ®Google Scholar
• PAKULSKI C, DYBKOWSKA K, DROBNIK L: [Brain barriers. Part II. Blood/cerebrospinal fluid barrier and cerebrospinal fluid /brain tissue barrier]. Neurol. Neurochir. Pol. (1998) 32:133-139.
   PubMedGoogle Scholar
• FOSSAN G, CAVANAGH ME, EVANS CA et al.: CSF-brain permeability in the immature sheep fetus: a CSF-brain barrier. Brain Res. (1985) 350:113-124.
   PubMedGoogle Scholar
• CZOSNYKA M, CZOSNYKA Z, MOMJIAN S, PICKARD JD: Cerebrospinal fluid dynamics. Physiol. Meas. (2004) 25:R51-R76.
   PubMed Web of Science ®Google Scholar
• FENSTERMACHER JD, GHERSI-EGEA JF, FINNEGAN W, CHEN JL: The rapid flow of cerebrospinal fluid from ventricles to cisterns via subarachnoid velae in the normal rat. Acta Neurochir. Suppl. (1997) 70:285-287.
   PubMedGoogle Scholar
• ABBOTT NJ: Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. (2004) 45:545-552.
   PubMed Web of Science ®Google Scholar
• TODD NV, MORROW J, DOH-URA K et al.: Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J. Infect. (2005) 50:394-396.
   PubMed Web of Science ®Google Scholar
• PARRY A, BAKER I, STACEY R, WIMALARATNA S: Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol. Neurosurg. Psychiatry (2007) (In Press).
   PubMedGoogle Scholar
• WHITTLE IR, KNIGHT RS, WILL RG: Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir. (2006) 148:677-679.
   PubMed Web of Science ®Google Scholar